Cardiac Electrophysiological (EP) Studies and Cardiac Ablation of Abnormal Electrical Rhythms

Pediatric SVT Medical-Therapy Documentation

For pediatric SVT, document the medical-therapy history and clinical context before requesting ablation. In infants and small children, ablation is generally reserved for SVT that is life-threatening or uncontrolled, ineffective, or not tolerated despite medical therapy; in larger children and adolescents, definitive ablation may also be considered to avoid chronic medication or for recurrent or persistent SVT.

• Document failed, contraindicated, or intolerable pharmacotherapy when applicable.
• Do not represent ablation as necessary when SVT is well controlled with medical therapy and there are no compelling clinical circumstances.

PVC Ablation After Medical Therapy

For PVC ablation, document the PVC burden and the treatment history supporting medical necessity. The record should show either a PVC burden greater than 15% of total beats or symptomatic PVCs for which medical or pharmacologic management is ineffective, contraindicated, not tolerated, or not preferred.

• Include ambulatory-monitoring results showing PVC burden, when applicable.
• Document symptoms or declining ventricular function and the relevant antiarrhythmic-medication response or rationale for not using medication.

Support Adjunctive EP Procedures

Left atrial and left ventricular pacing and recording are medically necessary only when performed as part of a medically necessary diagnostic EP study and supported by clinical documentation.

• CPT 93621: left atrial pacing and recording from the coronary sinus or left atrium.
• CPT 93622: left ventricular pacing and recording.
• The associated diagnostic EP study must be medically necessary under CPT 93619 or 93620.

Document Qualifying Ablation Criteria

For SVT ablation, document the qualifying arrhythmia, symptoms, age, and treatment rationale. Adult documentation should identify the applicable covered indication, such as AVRT or high-risk accessory-pathway findings, CTI-dependent atrial flutter, ineffective or contraindicated therapy for junctional tachycardia, recurrent symptomatic non-CTI-dependent flutter, symptomatic AVNRT, or symptomatic focal AT as an alternative to pharmacologic therapy.

• For ventricular-rhythm ablation, document adult age and either PVC burden >15% or symptomatic PVCs meeting the medical-management criterion; for ventricular arrhythmias, document ineffective, contraindicated, not tolerated, or not preferred medical therapy.
• For AF ablation, document the covered indication, including symptomatic AF with the required medication rationale, HFrEF with ejection fraction ≤40%, high-volume endurance athleticism, or PH with pulmonary vascular disease.

Document the Separate Additional Arrhythmia

An additional ablation code is supported only when a new, separate, and distinct spontaneous or induced arrhythmia requiring ablation is identified during a medically necessary primary ablation. Document the second arrhythmia and why it required treatment.

• The second arrhythmia must not have been previously diagnosed.
• Identify the primary procedure and the additional mechanism treated; applicable additional codes include CPT 93655 and 93657.

Pre-Procedure EP Study Evaluation

Before an invasive EP study, complete and retain a thorough history and physical examination and review baseline ECGs and, when available, ECGs obtained during the arrhythmia. Selective pre-procedure testing should be tied to the presentation and may include event monitoring, echocardiography or cardiac MRI, exercise testing, or coronary angiography.

• Document evaluation for structural heart disease, exercise-induced arrhythmia, or suspected coronary disease when relevant.
• Record medication-management instructions, including discontinuation of AV-nodal blockers and class I or III antiarrhythmics when clinically appropriate.
• Assess procedural risks such as major bleeding diathesis and acute lower-extremity venous thrombosis when femoral access is planned.

Clinical Indication and Diagnostic Evidence

Support EP-study requests with the clinical indication, symptom history, rhythm documentation, and the expected effect of the result on care. Covered or guideline-supported scenarios include selected ventricular-arrhythmia or sudden-death risk evaluation, SVT of unknown mechanism, symptomatic pre-excitation, selected syncope, and other cases in which EP findings will guide ablation, medication, pacing, or ICD management.

• Include relevant ECGs, ambulatory-monitoring results, structural-heart findings, ejection fraction, prior myocardial infarction or cardiomyopathy, and documented symptoms.
• For syncope, document that the cause remains unexplained after appropriate evaluation and that EP results will change management.
• For narrow- or wide-complex tachycardia, document frequency, tolerance, treatment response, and why mechanism clarification or ablation is needed.

Risk-Stratification Details

When requesting EP study for risk stratification, document the specific disease, symptoms, ventricular function, prior arrhythmia, and anticipated management decision. The record should explain why the patient falls within a supported risk-stratification scenario rather than an excluded indication.

• Relevant supported contexts include ischemic or nonischemic cardiomyopathy with syncope or ventricular-arrhythmia symptoms, selected adult congenital heart disease, cardiac sarcoidosis, arrhythmogenic right ventricular cardiomyopathy, and asymptomatic Brugada syndrome with a spontaneous type 1 pattern.
• Include meaningful expected survival when the requested EP result is being used to support ICD-related decisions.
• Do not rely on EP study solely to induce ventricular arrhythmia when ICD criteria are already met.

Atrial-Fibrillation and Pre-Excitation Documentation

Establish AF with ECG documentation or another accepted rhythm-recording method, and describe the clinical history and examination supporting the diagnosis. For pre-excitation or suspected accessory-pathway disease, include the delta wave or other ECG evidence, symptoms, arrhythmia characteristics, and the reason EP evaluation or targeted ablation would affect care.

• Accepted supporting records may include telemetry, Holter or event monitoring, implanted loop recorder, pacemaker or defibrillator data, and, rarely, prior EP-study findings.
• For AF beginning before age 30, document the unexplained early onset and the rationale for evaluating or treating a reentrant SVT.
• For AF with wide QRS, document why EP study is needed to distinguish ventricular tachycardia from aberrant or pre-excited supraventricular rhythm.

Arrhythmia and Syncope Workup

For arrhythmia or syncope evaluation, document the ECG or monitor findings, symptom correlation, frequency and tolerance of episodes, prior treatment, and the unresolved diagnostic or management question. EP study is most supportable when its result will guide therapy such as ablation, medication, pacing, or ICD placement.

• For unexplained syncope, document recurrent events and results of structural-heart evaluation and other appropriate testing, including tilt testing when relevant.
• For tachycardia, describe narrow- or wide-complex morphology, whether the mechanism remains uncertain, and whether drug therapy failed, caused concern, or is not preferred.
• For PVCs, couplets, or nonsustained VT, include symptoms, burden, ejection fraction, other risk factors, and whether ablation or further risk assessment is being considered.

Use Covered Diagnosis and Procedure Codes

Use the most appropriate covered diagnosis and procedure codes effective on the submission date. Claims without covered code(s) applicable to this policy may be denied as not covered.

• Verify code selection against the policy and current coding guidance before submission.
• Ensure the diagnosis code supports the documented indication and the procedure code reflects the service performed.

EP Study Results Must Change Management

Before submitting an EP study, confirm that the result is expected to change management. EP study is not warranted when the diagnosis is already certain and invasive findings would not influence therapy, or when symptoms and treatment decisions are already established independently of the study.

• Document the specific anticipated decision, such as ablation, medication selection, pacing, or ICD implantation.
• Avoid EP study for asymptomatic or mildly symptomatic findings without relevant risk factors or a management consequence.
• For known causes of syncope or bradyarrhythmia, explain why EP findings would alter treatment if requesting the study.

Limit EP Study for Asymptomatic Pre-Excitation

Asymptomatic pre-excitation may justify EP study for risk stratification in selected patients, but avoid routine invasive testing when the result will not affect management. Document the patient’s risk features and the intended decision before submission.

• Consider higher-risk circumstances such as prior cardiac arrest, unexplained syncope, high-risk occupation or activity, structural heart disease, or ventricular dysfunction.
• For low-risk young patients, include pathway-risk findings such as SPERRI and the rationale for deferring ablation or considering it at diagnostic study.